Dry powder aerosols of Nanoparticulate drugs
5 Assignments
0 Petitions
Accused Products
Abstract
There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.
-
Citations
80 Claims
-
1-50. -50. (canceled)
-
51. A propellant-based dry powder composition for pulmonary or nasal delivery comprising nanoparticulate drug particles and at least one propellant, wherein the nanoparticulate drug particles:
-
(a) comprise a poorly soluble drug in crystalline form, amorphous form, or a combination thereof; (b) have an effective average particle size of less than about 1000 nm, and (c) have at least one surface modifier adsorbed on the surface thereof. - View Dependent Claims (52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)
-
-
65. A method for making a propellant-based dry powder composition comprising nanoparticulate drug particles and at least one propellant, wherein:
-
(a) the drug particles are poorly soluble and are in crystalline form, amorphous form, or a combination thereof; (b) the drug particles have an effective average particle size of less than about 1000 nm, and (c) the drug particles have at least one surface modifier adsorbed on the surface thereof; wherein the method comprises milling at ambient pressure or under high pressure a dispersion comprising the poorly soluble drug, at least one surface modifier and a non-aqueous liquid propellant to obtain a nanoparticulate drug composition having an effective average particle size of less than about 1000 nm, followed by obtaining dry powder of a nanoparticulate drug composition. - View Dependent Claims (66, 67, 68, 69, 70, 71)
-
-
72. A method for making a propellant-based dry powder composition, comprising:
-
(a) obtaining dry powder of a nanoparticulate drug composition; and (b) dispersing the dry powder in at least one propellant, wherein the nanoparticulate drug composition;
(i) comprises a poorly soluble drug, (ii) has an effective average particle size of less than about 1000 nm, and (iii) has a surface modifier adsorbed on the surface of the drug particles. - View Dependent Claims (73, 74, 75, 76, 77, 78, 79, 80)
-
Specification